Get the Stockscreener App
75.76
4.80%
-3.82
Illumina Inc stock is traded at $75.76, with a volume of 3.71M.
It is down -4.80% in the last 24 hours and down -0.71% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$79.58
Open:
$79.5
24h Volume:
3.71M
Relative Volume:
1.44
Market Cap:
$12.33B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-7.6064
EPS:
-9.96
Net Cash Flow:
$546.00M
1W Performance:
-2.72%
1M Performance:
-0.71%
6M Performance:
-49.86%
1Y Performance:
-31.96%
1-Day Range:
$75.24
$79.78
1-Week Range:
$73.86
$80.86
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
75.76 | 12.33B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina, Inc. (NASDAQ:ILMN) Q1 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera - Investing.com
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera By Investing.com - Investing.com India
SEC ends probe of Illumina’s Grail acquisition - MedTech Dive
TD Cowen raises Illumina stock target to $89, maintains Hold rating - Investing.com UK
Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina, Merck, AstraZeneca, and Roche Dominate with their Contributions to Research, Product Approvals, and Partnerships - GlobeNewswire
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips - Nasdaq
Lab-on-a-Chip Market Insights: Growth, Trends & Forecast - openPR.com
Earnings call transcript: Illumina Q1 2025 beats EPS forecast but faces stock dip - Investing.com
Illumina Reports Q1 2025 Financial Results Amid Challenges - TipRanks
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions - MSN
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Nasdaq
Illumina confirms SEC has closed investigation into $8B Grail deal - Endpoints News
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts - Investing.com Canada
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (ILMN) Shares Drop 3% Despite Beating Q1 EPS Estimates - GuruFocus
Illumina’s (NASDAQ:ILMN) Q1 Sales Top Estimates - Yahoo Finance
Illumina: Q1 Earnings Snapshot - marketscreener.com
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat - Seeking Alpha
Illumina Cuts Guidance on Threat From Tariffs and China Ban - Bloomberg.com
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 - PR Newswire
Lobbying Update: $620,000 of ILLUMINA INC. lobbying was just disclosed - Nasdaq
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
Clinical Oncology Next-Generation Sequencing Market Size, - openPR.com
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Single Cell Genome Sequencing Market Deep Research 2025-2032 | - openPR.com
ILLUMINA Earnings Preview: Recent $ILMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Here’s Why Artisan Mid Cap Fund Decided to Exit Illumina (ILMN) - Yahoo Finance
Earnings To Watch: Illumina (ILMN) Reports Q1 Results Tomorrow - Yahoo Finance
Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Illumina, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2024ILMN - ACCESS Newswire
Case study: Professor Sir Shankar Balasubramanian FRS - Royal Society
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017ILMN - ACCESS Newswire
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Illumina (ILMN) and Ovation.io Launch Major Clinical Multiomic D - GuruFocus
June 13th Options Now Available For Illumina (ILMN) - Nasdaq
Illumina Partners With Ovation.io to Create GLP-1 Dataset for Drug Discovery - marketscreener.com
Illumina (ILMN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Illumina, Ovation.io launching first-of-kind GLP-1 dataset - TipRanks
Illumina and Ovation.io unveil large GLP-1 therapy dataset - Investing.com
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development - PR Newswire
Even after rising 3.7% this past week, Illumina (NASDAQ:ILMN) shareholders are still down 74% over the past five years - Yahoo Finance
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Illumina, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineILMN - ACCESS Newswire
Canaccord Reduces Price Target for Illumina (ILMN) Amid Economic Challenges | ILMN Stock News - GuruFocus
When (ILMN) Moves Investors should Listen - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Digital Genome Market Set to Witness Significant Growth - openPR.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc. (ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
The path to precision medicine in Indonesia - Illumina
Computational Biology Market New Product Development & Latest - openPR.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):